
Dr. Vimal Prajapati
Dr. Prajapati completed his dermatology residency at the University of Alberta, earning certification in both Canada and the United States. He then pursued an additional 1-year fellowship in pediatric dermatology at Harvard Medical School. Dr. Prajapati has received 20 major awards; authored 1 textbook chapter; published 43 peer-reviewed manuscripts in print or electronic format; and presented 48 abstracts at scientific meetings regionally, nationally, as well as internationally. He also conducts clinical trials for both adults and children, with participation in 69 studies as an investigator or steering committee member.
Dr. Prajapati is a Clinical Associate Professor at the University of Calgary as well as co-founder and co-director of Skin Health & Wellness Centre, Dermphi Centre, and Dermatology Research Institute. Additionally, he has started several subspecialty initiatives, including multidisciplinary pediatric morphea, pediatric scleroderma, and pediatric psoriasis clinics in Calgary as well as rapid access psoriasis and rapid access eczema clinics in Calgary plus rural outreach psoriasis and rural outreach eczema clinics Medicine Hat.
Nov 24
Does seasonal variation impact the efficacy and safety/tolerability of a new topical retinoid in acne management?
Nov 25
Let’s talk GPP!
In the broad category of psoriasis lies many diseases, including the broadly known and prevalent plaque psoriasis, as well as the far less common, and rare, conditions such as guttate, inverse, erythrodermic and pustular psoriasis. Despite sharing the term psoriasis, generalized pustular psoriasis (GPP) is a distinct condition whose disease pathway is different than the far more common plaque psoriasis. This open session will serve to provide a comprehensive review of GPP, including disease mechanisms and patient prevalence/predispositions. The conversation will then dive into the burden of disease and truly call to light the unmet needs that currently exists with patients suffering with GPP. Those in attendance will gain a better understanding of this rare disease.
Learning Objectives
Nov 26
I Can I Am: Reaching New Possibilities with the Canadian and American Clinical Experience with Tildrakizumab
Clinical trial data suggests what can be done (I Can), while clinical experience presents what is possible (I Am). Dr. Parbeer Grewal will provide an overview of what can be done, which will be followed by a panel discussion with Canadian dermatologist Dr. Vim Prajapati and American dermatologist Dr. George Han to understand what is possible based on real-world clinical experience with tildrakizumab through the presentation of patient cases. The session will conclude with an opportunity for the audience to pose questions to the panel.
Nov 26
Challenges in treating plaque psoriasis to target: special sites and managing inadequate response
Friday APR 8, 2022
Beyond the Skin: The Feasibility and Value of Systematic Screening for Psoriatic Arthritis
Dermatologists are the gatekeeper to identifying patients with early signs of PsA. However, many dermatologists do not routinely consider screening for possible signs and symptoms of psoriatic arthritis – a common psoriasis comorbidity that causes irreversible joint damage and aggravates co-morbidities.
The data from Phase 1 of the PsA Screening Project will be presented. In an initial assessment survey of 52 Canadian dermatologists, only 17% will screen their moderate-to-severe psoriasis patients for psoriatic arthritis at every follow-up visit. When screening for PsA, only 9% of respondents rely on a validated screening questionnaire. When PsA is suspected, over 50% of dermatologists will refer to a rheumatologist reflecting a need for greater comfort in managing PsA patients in dermatology practice and when appropriate, initiating a referral to rheumatologist. The PsA Screening Project had dermatologists from across the country screen patients using 3 different tools, to establish which tool type was preferred, and what barriers exist that prevent them from adequately screening.
Session Learning Objectives:
- Recognize the impact of frequent screening for PsA on early detection
- Demonstrate the value of using a standardized screening tool for PsA in dermatology practice
- Consider best practices for implementation of systematic screening to improve patient outcomes
Saturday APR 9, 2022
Innovations in Topical Therapy: The Role of Vehicle in Treatment Decisions
This session will present audience members with a brief overview around the importance of vehicle formulation in immunodermatologic treatment. The content of the session will focus on current topical therapies as well potential future vehicle formulations while considering the clinical implications of the differences between various vehicle formulations. The session will consider the role of vehicle formulation across different regions of the body and examine factors that may influence patient adherence to therapy.
Objectives:
- To discuss the importance of vehicle in immunodermatologic treatment
- To examine opportunities for advancements with current topical therapies
- To consider potential future vehicle formulation(s)